09.07.2020 Novavax Daily Analysis
NVAX was in the news this week as it
received $1.6 billion from Operation Warp Speed to complete late-stage clinical development, establish large-scale manufacturing, and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020.
It’s the largest contribution from Operation Warp Speed thus far, and many consider NVAX to be one of the leaders.
The company’s vaccine aims to increase the body’s production of antibodies to block the protein that the coronavirus uses to invade cells. NVAX is expected to report the results of its phase 2 trial later this month and begin a final-stage study with 30,000 participants this fall.